Description:

Founded in Dublin in 2015, ATXA Therapeutics Ltd (ATXA) is a clinical-stage pharmaceutical company bringing its proprietary drugs through clinical development in the heart and lung diseases area. In this, ATXA’s initial target diseases are forms of pulmonary hypertension as well as certain types of heart disease. ATXA’s lead drug, called NTP42, along with other pipeline drugs, have a wider potential to treat a range of other blockbuster diseases, also with high unmet medical needs for new and improved therapies.